The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ABBVIE INC. COM 00287Y109 94 1,000 SH   SOLE   1,000 0 0
ALLERGAN PLC SHS G0177J108 65,525 344,000 SH   SOLE   344,000 0 0
BIOGEN INC. COM 09062X103 163,179 461,858 SH   SOLE   461,858 0 0
INNOVIVA INC. COM 45781M101 69,113 4,535,000 SH   SOLE   4,535,000 0 0
INTERCEPT PHARMACEUTICALS INC. COM 45845P108 32,537 257,500 SH   SOLE   257,500 0 0
IRONWOOD PHARMACEUTICALS INC. COM CL A 46333X108 62,156 3,367,100 SH   SOLE   3,367,100 0 0
MEDICINES CO. COM 584688105 57,487 1,922,000 SH   SOLE   1,922,000 0 0
NOVELION THERAPEUTICS INC. COM NEW 67001K202 3,034 1,025,000 SH   SOLE   1,025,000 0 0
SHIRE PLC SPONSORED ADR 82481R106 181 1,000 SH   SOLE   1,000 0 0